Dr Manuel A Gargallo-Fernandez
Endocrinology Department
Hospital Infanta Leonor
Fundacion Jimenes Diaz
Madrid
Spain
Dr Charles Young BSc
Editor-in-Chief IJCP
January 6, 2021
Dear Dr. Young:
I am pleased to submit an original research article entitled
“REAL-WORLD CLINICAL OUTCOMES ASSOCIATED WITH CANAGLIFLOZIN IN PATIENTS
AGED 65 YEARS AND OLDER WITH TYPE 2 DIABETES MELLITUS IN SPAIN: THE OLD
REAL-WECAN STUDY” for consideration for publication in theInternational Journal of
Clinical Practice.
We have previously reported the effectiveness of canagliflozin 100 and
the switch to canagliflozin 300 from a prior SGLT-2i in patients with
T2DM in a real world setting (Gorgojo-Martínez JJ,
Gargallo-Fernández MA, Galdón Sanz-Pastor A, Antón-Bravo T,
Brito-Sanfiel M, Wong-Cruz J. Real-World Clinical Outcomes Associated
with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain:
The Real-Wecan Study. J Clin Med. 2020; 9: 2275 ), now this manuscript
show the subanalysis results of our prior study to assess the
effectiveness and safety of canagliflozin in patients aged> 65 years.
Given the scarce data about effectiveness of canagliflozin in older
patients, and the lack of data about switching to canagliflozin 300 from
any SGLT-2i in the increasing number of T2DM patients older than 65
years, we believe that this manuscript is appropriate for publication by